LLDFVRFMGV

The LLDFVRFMGV peptide is derived from the Epstein-Barr virus nuclear antigen 6 (EBNA6), a protein expressed during the latent phase of EBV infection. EBNA6 plays a role in B-cell transformation and immortalization. Peptides from EBNA6 are utilized in research to study EBV latency and associated immune responses. Understanding T-cell responses to EBNA6-derived epitopes can provide insights into EBV-associated diseases and inform vaccine design.

LLDFVRFMGV is a 10-residue synthetic peptide with the sequence Leu-Leu-Asp-Phe-Val-Arg-Phe-Met-Gly-Val. The sequence has a relatively high hydrophobic-residue fraction that can influence aqueous solubility and surface adsorption. These sequence-derived properties describe the reagent chemically; no specific receptor, enzyme, pathway, disease association, or biological activity is assigned without product-specific experimental evidence.

• LC-MS/HPLC analytical method development
• sequence-specific assay controls

Sequence-derived chemical properties support reagent selection and experimental planning but do not establish biological function. Solubility, aggregation, adsorption, conjugation efficiency, and assay performance should be validated under the intended experimental conditions.